Drug intelligence / Profile preview

VDL-309

Development stage: Preclinical
Lead developer: Vascurie
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

VDL-309 is a preclinical-stage monoclonal antibody developed by Vascurie that targets CD93, a transmembrane glycoprotein involved in angiogenesis, cell-cell adhesion, and vascular remodeling. Specifically designed for neuro-oncology, VDL-309 aims to treat central nervous system (CNS) tumors by modulating the tumor microenvironment and inhibiting pathological blood vessel formation associated with tumor growth. The candidate is being refined through a collaboration with AAX Biotech, utilizing their Seqitope platform for high-resolution epitope mapping to optimize candidate selection and therapeutic efficacy for brain and CNS cancers.

Targets

CD93 (CD93 antigen)

Beyond the preview

Go deeper on VDL-309.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VDL-309.

Explore the full profile